In NASH animal models, the flavonoid myricetin has been observed to inhibit interactions between the TREM-1-TLR2/4-MyD88 signaling pathway and hepatic M1 macrophages, leading to decreased hepatic inflammation and fibrosis (Yao et al., 2020). The gene discussed is MYD88; the disease is metabolic dysfunction-associated steatohepatitis.